Waheed Z. Jamal
Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany
Ingelheim Am Rhein, RP 55216, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Empagliflozin after Acute Myocardial Infarction.
Journal: The New England journal of medicine
Published: April 08, 2024
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
Journal: Journal of the American College of Cardiology
Published: February 22, 2024
A social enterprise model for TB detection and treatment through the private sector in Pakistan.
Journal: IJTLD open
Published: August 10, 2023
Empagliflozin and Major Renal Outcomes in Heart Failure.
Journal: The New England journal of medicine
Published: August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Journal: The New England journal of medicine
Published: August 27, 2021
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
Journal: Journal of the American College of Cardiology
Published: May 25, 2021
Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial.
Journal: European journal of heart failure
Published: April 15, 2021
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
Journal: Journal of the American College of Cardiology
Published: January 11, 2021
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Journal: Journal of the American College of Cardiology
Published: December 28, 2020
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
Journal: European journal of heart failure
Published: November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Journal: Circulation
Published: November 11, 2020
Last Updated: 09/26/2026